Zomedica Corp. [AMEX: ZOM] price surged by 3.44 percent to reach at $0.01. The company report on May 8, 2023 at 6:30 AM that Zomedica Exercises Option to Acquire Structured Monitoring Products.
Zomedica Corp. (NYSE American:ZOM) (‘Zomedica’ or the ‘Company’), today announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc. (SMP), the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price. Exercising this option began a period where the companies have agreed to work together to complete due diligence and negotiate a definitive acquisition agreement.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The VetGuardian system improves the quality of care of pets during recovery from surgery, and for those staying in clinic overnight by providing real time remote monitoring of the pet’s vital signs with the ability to alert staff if the vital signs exceed preset ranges. Its unique patented doppler technology allows the VetGuardian system to read vital signs in real time without wired leads, or a harness on the pet, thus allowing the pet to rest comfortably during recovery.
A sum of 4105638 shares traded at recent session while its average daily volume was at 3.79M shares. Zomedica Corp. shares reached a high of $0.22 and dropped to a low of $0.21 until finishing in the latest session at $0.22.
The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Zomedica Corp. [ZOM]:
Dawson James have made an estimate for Zomedica Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 06, 2023.
The Average True Range (ATR) for Zomedica Corp. is set at 0.01, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 10.93. The Price to Book ratio for the last quarter was 0.81, with the Price to Cash per share for the same quarter was set at 0.12.
ZOM Stock Performance Analysis:
Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.46. With this latest performance, ZOM shares gained by 2.48% in over the last four-week period, additionally sinking by -5.35% over the last 6 months – not to mention a rise of 4.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 57.31, with the RSI for the last a single of trading hit 65.04, and the three-weeks RSI is set at 53.10 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2165, while it was recorded at 0.2096 for the last single week of trading, and 0.2330 for the last 200 days.
Insight into Zomedica Corp. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -115.81 and a Gross Margin at +50.77. Zomedica Corp.’s Net Margin is presently recorded at -89.88.
Return on Total Capital for ZOM is now -8.10, given the latest momentum, and Return on Invested Capital for the company is -6.30. Return on Equity for this stock declined to -6.32, with Return on Assets sitting at -6.08. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 0.65. Additionally, ZOM Total Debt to Total Capital is recorded at 0.65, with Total Debt to Total Assets ending up at 0.62. Long-Term Debt to Equity for the company is recorded at 0.41, with the Long-Term Debt to Total Capital now at 0.41.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$200,176 per employee. Receivables Turnover for the company is 14.40 with a Total Asset Turnover recorded at a value of 0.07.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.50 and a Current Ratio set at 15.80.
Zomedica Corp. [ZOM] Insider Position Details
There are presently around $20 million, or 9.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 48,820,270, which is approximately 5.377% of the company’s market cap and around 1.33% of the total institutional ownership; BLACKROCK INC., holding 11,299,690 shares of the stock with an approximate value of $2.48 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $2.45 million in ZOM stock with ownership of nearly 0% of the company’s market capitalization.
29 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 3,900,444 shares. Additionally, 24 investors decreased positions by around 2,208,244 shares, while 46 investors held positions by with 87,416,702 shares. The mentioned changes placed institutional holdings at 93,525,390 shares, according to the latest SEC report filing. ZOM stock had 11 new institutional investments in for a total of 193,713 shares, while 12 institutional investors sold positions of 1,195,686 shares during the same period.